DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
BACKGROUND
Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml(-1). DBS can increase access to IM therapeutic drug monitoring.


RESULTS
IM was measured in the range 50-4000 ng ml(-1) by UHPLC-MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40°C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml(-1) in DBS identified 93% of patients with plasma concentration below 1000 ng ml(-1).


CONCLUSIONS
IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma.
Instituto de Ciências da Saúde, Universidade Feevale, Novo Hamburgo, RS, Brazil.
Marina Venzon
MV
Antunes
Instituto de Ciências da Saúde, Universidade Feevale, Novo Hamburgo, RS, Brazil.
Suziane
S
Raymundo
Instituto de Ciências da Saúde, Universidade Feevale, Novo Hamburgo, RS, Brazil.|Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre-RS, Brazil.
Sandrine Comparsi
SC
Wagner
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre-RS, Brazil.
Vanessa Suñé
VS
Mattevi
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre-RS, Brazil.
Natalia
N
Vieira
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre-RS, Brazil.
Renata
R
Leite
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre-RS, Brazil.
Fabiola
F
Reginato
Grupo Hospitalar Conceição, Porto Alegre-RS, Brazil.
Marcelo Zanella
MZ
Capra
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Laura
L
Fogliatto
Instituto de Ciências da Saúde, Universidade Feevale, Novo Hamburgo, RS, Brazil.
Rafael
R
Linden
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D059788:Dried Blood Spot Testing / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006400:Hematocrit; D006801:Humans; D000068877:Imatinib Mesylate / Q000097:blood* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires; D053719:Tandem Mass Spectrometry / Q000379:methods; D055815:Young Adult
D000068877:Imatinib Mesylate